Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft, and Caleb Finch in 1996 and is headquartered in Charlottesville, VA.
Clinical Trials
4
2 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1996
Active, not recruiting
2
50.0%
Completed
2
50.0%
No approval data available
- Northwestern University researchers discovered that experimental drug NU-9 dramatically reduces toxic amyloid beta oligomers and prevents early brain inflammation in pre-symptomatic Alzheimer's disease mouse models. - The study identified a previously unknown highly toxic amyloid beta oligomer subtype called ACU193+ that appears to drive neuronal dysfunction and inflammation decades before symptoms emerge. - NU-9 demonstrated brain-wide anti-inflammatory effects by significantly reducing reactive astrogliosis and abnormal TDP-43 protein accumulation after 60 days of daily oral treatment. - The findings suggest NU-9 could serve as a prophylactic intervention for individuals with Alzheimer's biomarkers, similar to cholesterol-lowering drugs for heart disease prevention.
- Acumen Pharmaceuticals and JCR Pharmaceuticals demonstrated 15 to 68-fold increases in brain penetration for Alzheimer's antibodies using transferrin receptor technology, addressing the critical challenge that typically less than 1% of intravenous antibodies reach the brain. - The enhanced brain delivery technology preserved the potency and selectivity of sabirnetug (ACU193) for toxic amyloid beta oligomers in mouse models while potentially limiting exposure to vascular amyloid. - Analysis of the Phase 2 ALTITUDE-AD trial recruitment data revealed that site databases and physician referrals were the most effective methods among six strategies tested, with 542 patients enrolled from 2,362 screened across 76 sites. - The companies are now developing transferrin receptor-targeting antibodies for clinical testing to maximize the efficacy-to-safety ratio of Alzheimer's treatments.
- Acumen Pharmaceuticals has dosed the first participant in the open-label extension portion of its Phase 2 ALTITUDE-AD trial for sabirnetug (ACU193) in early Alzheimer's disease. - The extension study will provide all 542 participants who completed the 18-month placebo-controlled trial with access to sabirnetug at 35 mg/kg intravenously for an additional 52 weeks. - Sabirnetug is the first humanized monoclonal antibody to demonstrate selective target engagement of toxic soluble amyloid beta oligomers in Alzheimer's patients. - The company expects to report topline results from the main ALTITUDE-AD study in late 2026, with the extension providing valuable long-term safety and efficacy data.
- Acumen Pharmaceuticals expects topline results from its Phase 2 ALTITUDE-AD study evaluating sabirnetug for early Alzheimer's disease in late 2026, with the trial having enrolled 542 participants. - The company announced a collaboration with JCR Pharmaceuticals to develop Enhanced Brain Delivery therapy combining Acumen's oligomer-targeting antibodies with JCR's blood-brain barrier-penetrating technology. - Sabirnetug demonstrated 8,750-fold selectivity for amyloid beta oligomers over monomers and achieved the highest binding affinities among tested monoclonal antibodies in surface plasmon resonance testing. - The company maintains $166.2 million in cash reserves expected to support operations into early 2027, while implementing cost-efficient screening strategies that reduced trial costs by approximately 40%.
- Acumen Pharmaceuticals and JCR Pharmaceuticals have entered a strategic collaboration to combine Acumen's amyloid beta oligomer-selective antibody expertise with JCR's blood-brain barrier-penetrating J-Brain Cargo® technology for Alzheimer's disease treatment. - The partnership aims to develop Enhanced Brain Delivery therapy using sabirnetug or other novel antibodies, with preclinical candidate data expected in early 2026 and exclusive option rights for up to two development candidates. - Acumen's lead program sabirnetug is currently in Phase 2 ALTITUDE-AD trial with 542 enrolled patients, having demonstrated selective target engagement and statistically significant amyloid plaque reduction in Phase 1 studies. - JCR's transferrin receptor-targeting platform has already produced an approved therapy in Japan for lysosomal storage disorders, providing validated safety profile for the blood-brain barrier delivery technology.
- Biogen presents 48-month data from LEQEMBI's Clarity AD open-label extension study and introduces subcutaneous formulation for maintenance dosing at AAIC 2025. - The company shares baseline characteristics from CELIA Phase 2 trial evaluating BIIB080, an investigational antisense oligonucleotide therapy targeting tau protein. - Acumen Pharmaceuticals demonstrates cost savings from pTau217 screening in its ALTITUDE-AD Phase 2 trial and presents selectivity data for sabirnetug targeting toxic amyloid beta oligomers.
- Northwestern University researchers found that NU-9, an experimental drug approved for ALS clinical trials, effectively reduces toxic protein buildup in Alzheimer's disease animal models. - The drug works by enhancing cellular recycling mechanisms, specifically targeting lysosomes and the enzyme cathepsin B to break down harmful protein clusters that cause neurodegeneration. - NU-9 demonstrated dual benefits in animal studies: reducing amyloid beta oligomer accumulation and decreasing brain inflammation, with treated mice showing improved performance on memory tests.
- Acumen Pharmaceuticals is progressing its Phase 2 ALTITUDE-AD trial of sabirnetug, an immunotherapy for Alzheimer's, with enrollment expected to complete in H1 2025. - The company's Phase 1 trial showed sabirnetug was well-tolerated and reduced amyloid plaque load, supporting its continued development for early Alzheimer's disease. - A collaboration with Halozyme, Inc. is underway to develop a subcutaneous formulation of sabirnetug, with Phase 1 PK comparison trial results anticipated in Q1 2025. - Acumen's Q3 2024 report reveals increased R&D spending due to clinical trial advancements, with sufficient funds to operate into the first half of 2027.
- Acumen Pharmaceuticals presents data on pTau217 assay for efficient screening in the ALTITUDE-AD trial, reducing the need for invasive procedures. - The pTau217 assay identifies potential participants with a higher likelihood of amyloid accumulation, improving the efficiency of patient selection. - ALTITUDE-AD, a Phase 2 trial, evaluates sabirnetug in early Alzheimer's, with enrollment expected to complete in the first half of 2025. - The screening strategy reduces burden for patients and investigators, fostering a more compassionate and sustainable clinical trial experience.
- Acumen Pharmaceuticals is using a validated plasma pTau217 assay to screen participants for its Phase 2 ALTITUDE-AD trial of sabirnetug in early Alzheimer's disease. - The pTau217 assay identifies individuals with Alzheimer's pathology, streamlining the enrollment process for the clinical trial. - Sabirnetug (ACU193) is a humanized monoclonal antibody targeting soluble amyloid beta oligomers, a toxic form of amyloid beta implicated in Alzheimer's. - The ALTITUDE-AD trial is a Phase 2 study evaluating the efficacy and safety of sabirnetug in slowing cognitive and functional decline in early Alzheimer's patients.
